Sophia Antipolis, France - Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced it will hold a webcast on Monday, March 18, 2024, at 18:00 CET.
In light of its recently announced debt restructuring and cost reduction, Nicox's Chief Executive Officer Gavin Spencer will provide an update on the Company's strategic and financing perspectives and plans for 2024 and 2025. Professor Philippe Denis, Head of Ophthalmology at the Croix-Rousse University Hospital, Lyon, France, and a leading expert in the field, will give a presentation on glaucoma, its treatments and the potential use of NCX 470.
The presentations will be followed by a Q&A session. You are kindly invited to submit your questions in advance to communications@nicox.com or using the chat function during the event.
The webcast will take place in French and a replay will be available afterwards on the Investor section of the Nicox website.
About Professor Philippe Denis
Prof. Denis is Professor and Chair of the Department of Ophthalmology of Croix-Rousse University Hospital of Lyon, France, with significant expertise in the treatment of glaucoma. He is also Director of the Optometry School of Lyon, Chairman of the College of Ophthalmology of Lyon and Director of the Ophthalmic Educational Council for Auvergne Rhone-Alpes Region. Prof. Denis is the President of the French Society of Glaucoma (SFG) and was previously President of the French Society of Ophthalmology (SFO).
After completing ophthalmology training in Paris, Prof. Denis worked in the French West Indies and then moved to the University Hospital of Lyon. In 1990, he won the Chibret International Award in Singapore for his research in the field of retinal adrenergic receptors. He was also a recipient of the French Society of Ophthalmology Award and of the Paris University Thesis Award. Prof. Denis has had more than 100 international papers related to glaucoma published in peer-reviewed publications and has written several books and book chapters.
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.
Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.
Contact:
Nicox Gavin Spencer
Tel: +33 (0)4 97 24 53 00
Email: communications@nicox.com
Tel: +33 (0)4 97 24 53 00
NICOX SA 
